Search Results

You are looking at 1 - 10 of 1,089 items for :

  • Refine by Access: All x
Clear All
Full access

Optimal Management of Localized Renal Cell Carcinoma: Surgery, Ablation, or Active Surveillance

David Y. T. Chen and Robert G. Uzzo

Edited by Kerrin G. Robinson

. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients . Ann Surg 1999 ; 230 : 1 – 8 . 30 Dupuy DE Zagoria RJ Akerley W . Percutaneous radiofrequency ablation of malignancies in the lung . AJR

Full access

Liver-Directed Therapies for Hepatocellular Carcinoma

Cletus A. Arciero and Elin R. Sigurdson

comparison of radio-frequency thermal ablation versus percutaneous ethanol injection . Radiology 2003 ; 228 : 235 – 240 . 36. Livraghi T Bolondi L Lazzaroni S . Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in

Full access

Photodynamic Therapy in Cholangiocarcinoma

Michel Kahaleh

Endoscopic Biliary Drainage “From an endoscopy standpoint, knowing the different segments of the liver is crucial in terms of being able to provide biliary decompression,” declared Dr. Kahaleh. “Everything we do is based on symptoms and imaging,” he added

Full access

Endoscopic Therapy of Esophageal Premalignancy and Early Malignancy

Thomas B. Nealis, Kay Washington, and Rajesh N. Keswani

's esophagus cases to reduce the risk of synchronous or metachronous lesions. Complete remission ranges from 94% to 97% for patients undergoing CBE-EMR for HGD or intramucosal adenocarcinoma, with focal radiofrequency ablation used in some cases. 54 However

Full access

CLO20-044: Laparoscopic Microwave Ablation for the Treatment of Primary and Metastatic Liver Malignancies

Adrian Legaspi, Vanitha Vasudevan, Amit Sastry, and Jeronimo Garcialopez de Llano

laparoscopic, ultrasound-guided microwave ablation (LMA) for the management of primary and metastatic malignancy to the liver alone or in combination with additional loco-regional therapy (Y-90 radioembolization) and/or systemic chemotherapy or immunotherapy

Full access

Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer

Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond, and Mark S. Carey

use in premenopausal women, there are long-term risks of ovarian ablation (OA), which is a necessary additional intervention in women who still have ovarian function. A recent study found that OA preceeding an AI (OA/AI) was more costly and less

Full access

BPI24-013: Microwave Ablation Versus Resection Versus Stereotactic Body Radiation Therapy of Stage IA Non–Small Cell Lung Cancer in US Veterans

Ericson John Torralba, Garrett Fisher, Reid Fursmidt, Michael Gilbert, Perry Nystrom, Albert Malcom, John Mathis, and Robert Short

Purpose: We describe a midterm comparison of microwave ablation (MWA), stereotactic body radiation therapy (SBRT), and resection as primary therapy for early-stage non-small cell lung cancer (NSCLC) in a US veteran population. Materials and

Full access

Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study

En Cheng, Peiyin Hung, and Shi-Yi Wang

Evidence-based HCC management guidelines have been updated to take full advantage of current treatment options, including transplantation, surgical resection, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), transarterial

Full access

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

Tamoxifen for Longer Against Shorter (ATLAS) Trial is comparing 5 to 10 years, and the Adjuvant Tamoxifen Treatment Offer More (ATTOM) trial is comparing 5 years with various longer durations. Ovarian Ablation or Suppression in the Premenopausal Setting The

Full access

Modern Approaches to Localized Cancer of the Esophagus

Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy, and Jaffer A. Ajani

, preferably, endoscopic mucosal resection (EMR) biopsy of the lesion to evaluate for submucosal extension. For patients with a T1aN0M0 tumor, treatment options include EMR with negative pathologic margins and ablation of at-risk adjacent mucosa or